Novo Nordisk escalated its legal battle against Eli Lilly, seeking a court order to stop Lilly's comparative advertising for its GLP-1 drugs, a move that highli

Eli Lilly's triple agonist retatrutide met Phase III endpoints, positioning it as a potentially more powerful obesity drug and setting up a regulatory filing.

The FDA approved GSK's Jideytro for lung cancer, marking the company's first entry into the lung cancer market shortly after closing the Nuvalent deal.

The Trump administration's proposed tariffs aim to reshore generic drug manufacturing, threatening India's pharmaceutical export industry and potentially raisin

A report outlines unexpected side effects from GLP-1 obesity drugs such as Wegovy and Mounjaro, including impacts on pregnancy and hair loss, adding to safety s

Roche is halting development of one obesity drug candidate from its Carmot acquisition while advancing another that it believes has best-in-class potential.

A mid-stage trial showed an experimental GLP-1 drug reduced fatty liver disease regardless of weight loss, offering a potential new treatment pathway for MASH.

Intellia Therapeutics shares jumped as investors anticipate the first Phase 3 data readout for a gene-editing therapy, a key milestone for the CRISPR field.

Samsung Biologics acquired Swiss peptide manufacturer PolyPeptide for $1.8 billion, expanding its contract development capabilities amid US efforts to onshore g

The FDA approved the first eye-specific formulation of bevacizumab for wet age-related macular degeneration, offering a potentially lower-cost treatment option.

Pfizer shares fell after a lung cancer trial failure dampened enthusiasm for its breast cancer drug Ibrance's positive data.

A fatal incident in a Chinese gene-editing trial has sparked renewed debate over ethical standards and regulatory oversight in the field.

Stanford researchers used AI to identify a naturally occurring molecule with GLP-1-like effects but fewer side effects than current drugs.

Shares of Sellas Life Sciences gained after the company reported promising survival data for its AML treatment ahead of a CEO media appearance.

The European Union approved AstraZeneca's Etcamah for advanced breast cancer, expanding its oncology portfolio.

AbbVie received FDA approval for a drug targeting a rare blood cancer, boosting its hematology pipeline.

Corcept Therapeutics raised its full-year earnings guidance significantly, sending shares higher as analysts updated their forecasts.

Shares of Cue Biopharma more than doubled in after-hours trading, with investors speculating on a catalyst.